ClinicalTrials.gg
RecruitingNCT07535593Wells-DoC IIUpdated Aug 5, 2026

Transcutaneous Electrical Acupoint Stimulation at Jing-Well Points for Disorders of Consciousness

A Phase 2/3 interventional study of Transcutaneous electrical stimulation and Sham electrical stimulation in Disorders of Consciousness Due to Severe Brain Injury, sponsored by Xijing Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Xijing Hospital · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Consciousness Disorders with a site in China — 30 open to participants now, 31 under way, 1 of them phase 3. Consciousness Disorders · China.

Planned enrollment
6th of 40
160 · median 60
Started
2026
with 7 others
Phase 2/3
Only one
of the 70
Primary completion
2028-06
later than 29 of 30 live
Registered
68th of 70
by date
Lead sponsor
7 of 70
Xijing Hospital

Among the 70 studies in Consciousness Disorders with a site in China, this one is the 6th largest by planned enrollment of the 40 interventional ones that give a count, is one of 8 that started in 2026, is the only one in phase 2/3, reaches primary completion later than 29 of the 30 other live ones, and was the 68th registered.

Consciousness Disorders

291 studies on the registry are indexed under Consciousness Disorders; 109 are open to participants now.

Browse Consciousness Disorders studies →

Open to participants now

30 of the 70 studies in Consciousness Disorders with a site in China are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 74 Consciousness Disorders studies recruiting now, 31 (42%) set no upper age limit and 24 (32%) stop at 75 or younger; 12 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Consciousness Disorders with a site in China, or all of them as a file.
02

Study summary

Effective treatment options for disorders of consciousness (DoC) remain limited, and available interventions show heterogeneous efficacy. To date, limited evidences support the use of amantadine and transcranial direct current stimulation in this population.

Bloodletting puncture (BP) at the hand twelve Jing-Well points (HTWPs) has been traditionally used in China as an empirical therapy for DoC; however, its efficacy has not been established by robust clinical evidence. Transcutaneous electrical acupoint stimulation (TEAS) provides a modern, noninvasive alternative for acupoint stimulation. The Wells-DoC trial, a multicenter, randomized, controlled, open-label study with blinded endpoint assessment, provided preliminary evidence that TEAS applied at the hand twelve Jing-Well points was associated with a numerically higher proportion of consciousness improvement in patients with DoC, although the difference did not reach statistical significance. These findings support the need for further evaluation in an adequately powered randomized controlled trial.

The Wells-DoC II trial is a multicenter, randomized, controlled, double-blind clinical trial designed to evaluate the efficacy and safety of TEAS at the twelve Jing-Well points of the hand in patients with DoC. The primary objective of the Wells-DoC II trial is to determine whether TEAS applied at the twelve Jing-Well points of the hand improves consciousness in adults with DoC. The primary endpoint is the proportion of patients achieving consciousness improvement after 14 consecutive days of treatment, compared between the TEAS group and the sham stimulation (placebo control) group.

The secondary objectives are to assess the effects of TEAS versus sham stimulation on: (1) changes in Coma Recovery Scale-Revised (CRS-R) scores at 7 and 14 days; (2) change in ABCD model classification at day 14; and (3) functional outcomes measured by the Glasgow Outcome Scale-Extended (GOSE) at 3 and 6 months after enrollment.

A total of 160 patients will be recruited over a 28-month period.

03

Conditions studied

  • Disorders of Consciousness Due to Severe Brain Injury

Keywords

  • Transcutaneous Electrical Acupoint Stimulation
  • Hand Jing-Well Points
  • Disorders of Consciousness
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18-80 years old;
  • From 7 to 90 days since brain injury;
  • Diagnosed in VS/UWS or MCS as defined by at least two CRS-R assessments performed during the screening period
  • Acquired cerebral damage of known etiology
  • Intact hand skin
  • given by the legal surrogate

Exclusion criteria

Exclusion Criteria:

  • Patients who continuously receive sedative drugs and Na+ or Ca2+ channel blockers (e.g., carbamazepine) or NMDA receptor antagonists (e.g., dextromethorphan)
  • History of previous serious、progressive neurological disorder prior to the brain injury;
  • Epilepsy and seizure
  • Unstable vital signs or life-threatening comorbidities
  • Implanted devices: including cardiac pacemakers or implantable cardioverter-defibrillators (ICDs), deep brain stimulators, ventriculoperitoneal (VP) shunts, and other indwelling electronic or neurosurgical implants.
  • Documented pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Transcutaneous electrical stimulation group

    Patients randomized to the treatment group will receive transcutaneous electrical acupoint stimulation at hand twelve jing-well points for 14 consecutive days, twice a day, combined with conventional treatment or rehabilitation for patients with DoC.

    Device: Transcutaneous electrical stimulation

  • Sham comparator
    Sham electrical stimulation group

    Patients randomized to the Sham electrical stimulation group will receive sham electrical acupoint stimulation at hand twelve jing-well points for 14 consecutive days, twice a day, combined with conventional treatment or rehabilitation for patients with DoC.

    Device: Sham electrical stimulation

Interventions

  • DeviceTranscutaneous electrical stimulation

    Transcutaneous electrical acupoint stimulation at hand twelve jing-well points

  • DeviceSham electrical stimulation

    Sham electrical acupoint stimulation at hand twelve jing-well points

06

What researchers measure

Primary outcomes

  1. Proportion of consciousness improvement after 14 consecutive days of treatment

    The primary effectiveness outcome was the proportion of patients with consciousness improvement after 14 consecutive days of treatment, wherein improvements from unresponsive wakefulness syndrome (UWS)/vegetative state (VS) to minimally conscious state (MCS) or emergence from minimally conscious state (EMCS), from MCS minus (MCS-) to MCS plus (MCS+) or EMCS, or from MCS+ to EMCS signify a consciousness improvement. Diagnoses of UWS/VS, MCS (minus or plus) and EMCS were determined based on the presence of specific Coma Recovery Scale-Revised (CRS-R) subscale items, assessed by a trained neurologist. The hierarchical order of consciousness levels from worst to best is UWS/VS, MCS-, MCS+, and EMCS.

    Time frame: 14 days after treatment

Secondary outcomes

  1. Changes in Coma Recovery Scale-Revised (CRS-R) scores after 7 days of treatment

    CRS-R is composed of six subscales: auditory function, visual function, motor function, oromotor function, communication ability, and arousal level. CRS-R score ranges from 0 to 23, with higher scores mean a better outcome.

    Time frame: 7 days after treatment

  2. Changes in sub scale of Coma Recovery Scale-Revised (CRS-R) scores after 7 days of treatment

    CRS-R is composed of six subscales: auditory function, visual function, motor function, oromotor function, communication ability, and arousal level. CRS-R score ranges from 0 to 23, with higher scores mean a better outcome. Each sub scale consists of multiple hierarchically organized questions, with higher scores indicating greater performance.

    Time frame: 7 days after treatment

  3. Changes in Coma Recovery Scale-Revised (CRS-R) scores after 14 days of treatment

    CRS-R is composed of six subscales: auditory function, visual function, motor function, oromotor function, communication ability, and arousal level. CRS-R score ranges from 0 to 23, with higher scores mean a better outcome.

    Time frame: 14 days after treatment

  4. Changes in sub scale of Coma Recovery Scale-Revised (CRS-R) scores after 14 days of treatment

    CRS-R is composed of six subscales: auditory function, visual function, motor function, oromotor function, communication ability, and arousal level. CRS-R score ranges from 0 to 23, with higher scores mean a better outcome. Each sub scale consists of multiple hierarchically organized questions, with higher scores indicating greater performance.

    Time frame: 14 days after treatment

  5. Changes in ABCD model classification after 14 days of treatment

    This model classifies the power spectrum of resting-state EEG data into four categories: A, B, C, and D. Type A exhibit a power spectrum peak in the delta range (0-4 Hz), indicative of a completely disconnected thalamocortical network. Type B shows a primary power spectrum peak in the theta range (4-8 Hz), reflecting a severely disconnected thalamocortical network. Type C exhibits power spectrum peaks in both the theta (4-8 Hz) and beta (13-24 Hz) ranges, indicative of a moderately disconnected thalamocortical network. Type D shows power spectrum peaks in the alpha (8-13 Hz) and beta ranges, representing a fully intact thalamocortical network.

    Time frame: 14 days after treatment

  6. Functional outcomes measured by the Glasgow Outcome Scale-Extended (GOSE) at 3 months after enrollment

    Functional outcomes were assessed at 3 months after enrollment using the Glasgow Outcome Scale-Extended (GOSE; range 1-8, where higher scores indicate better functional outcomes).

    Time frame: 3 months after enrollment

  7. Functional outcomes measured by the Glasgow Outcome Scale-Extended (GOSE) at 6 months after enrollment

    Functional outcomes were assessed at 6 months after enrollment using the Glasgow Outcome Scale-Extended (GOSE; range 1-8, where higher scores indicate better functional outcomes).

    Time frame: 6 months after enrollment

  8. Incidence of adverse events during 6 months after enrollment

    The safety outcome was the incidence of adverse events during 6 months after enrollment.

    Time frame: 6 months after enrollment

  9. Incidence of severe adverse events during 6 months after enrollment

    The safety outcome was the incidence of severe adverse events during 6 months after enrollment.

    Time frame: 6 months after enrollment

  10. Incidence of adverse events prespecified for transcutaneous electrical stimulation during treatment

    The following adverse events are prespecified for transcutaneous electrical stimulation applied to the twelve Jing-Well points of the hand, including treatment intolerance: manifested as observable distress responses during stimulation, (e.g., painful facial expressions, moaning, crying, or involuntary head movements); local adverse effects: skin infection (e.g., redness, swelling, suppuration), subcutaneous ecchymosis, and skin burns (e.g., blistering or eschar formation) at stimulation sites; and systemic adverse effects: epileptic seizures temporally associated with the intervention.

    Time frame: from the first treatment on Day 1 to the completion of the last treatment on Day 14

  11. Incidence of severe adverse events prespecified for transcutaneous electrical stimulation during treatment

    The following adverse events are prespecified for transcutaneous electrical stimulation applied to the twelve Jing-Well points of the hand, including treatment intolerance: manifested as observable distress responses during stimulation, (e.g., painful facial expressions, moaning, crying, or involuntary head movements); local adverse effects: skin infection (e.g., redness, swelling, suppuration), subcutaneous ecchymosis, and skin burns (e.g., blistering or eschar formation) at stimulation sites; and systemic adverse effects: epileptic seizures temporally associated with the intervention. Serious adverse events (SAEs) are defined as any untoward medical occurrence that results in death, is life-threatening, requires or prolongs hospitalization, results in persistent or significant disability/incapacity

    Time frame: from the first treatment on Day 1 to the completion of the last treatment on Day 14

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — NOT YET DECIDED

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Jun 2028, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 17, 2026
StartActual
Apr 20, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Dec 2028
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07535593
Lead sponsor
Xijing Hospital
Responsible party
Sponsor
First posted
Apr 17, 2026
Start date
Apr 20, 2026
Primary completion
Jun 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Aug 5, 2026

Study contacts

Wen Jiang, Dr.
Contact
jiangwen@fmmu.edu.cn
+86 29 84771319
Zhirong Fan, Dr.
Contact
fzr1601@163.com
+86 29 84771319

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion